---
search:
  boost: 2 
---

# Anti-Migraine Agents, Acute

This is a subcategory of Central Nervous System (CNS) Agents.

## Formulary

### Preferred

| Preferred                             | Generic Name                                           | Quantity | Time (Days) |
|:--------------------------------------|:-------------------------------------------------------|:--------:|:-----------:|
| Imitrex Nasal Spray <sup>BvG QL</sup> | Sumatriptan Succinate Nasal Spray (all strengths)      |    8     |     30      |
| Naratriptan <sup>QL</sup>             | Naratriptan HCI Tab (all strengths)                    |    9     |     30      |
| Nurtec ODT <sup>QL ST</sup>           | Rizatriptan Benzoate (all strengths and formulations)  |    9     |     30      |
| Sumatriptan Inj <sup>QL</sup>         | Sumatriptan Succinate Subcutaneous Inj (all strengths) |    4     |     30      |
| Sumatriptan Tab <sup>QL</sup>         | Sumatriptan Succinate Tab (all strengths)              |    9     |     30      |
| Tosymra <sup>BvG QL</sup>             | Sumatriptan Succinate Nasal Spray (all strengths)      |    8     |     30      |

### Non-Preferred

| Non-Preferred                         | Generic Name                                       |         Quantity          |        Time (Days)        |
|:--------------------------------------|:---------------------------------------------------|:-------------------------:|:-------------------------:|
| Almotriptan                           |                                                    |                           |                           |
| Dihydroergotamine                     |                                                    |                           |                           |
| Eletriptan                            |                                                    |                           |                           |
| Ergomar                               |                                                    |                           |                           |
| Frovatriptan                          |                                                    |                           |                           |
| Migergot                              |                                                    |                           |                           |
| Onzetra Xsail <sup>QL</sup>           | Sumatriptan Succinate Nasal Powder (all strengths) | Determined pursuant to PA | Determined pursuant to PA |
| Reyvow                                |                                                    |                           |                           |
| Sumatriptan / Naproxen                |                                                    |                           |                           |
| Sumatriptan Nasal Spray <sup>QL</sup> | Sumatriptan Succinate Nasal Spray (all strengths)  | Determined pursuant to PA | Determined pursuant to PA |
| Trudhesa                              |                                                    |                           |                           |
| Ubrelvy                               |                                                    |                           |                           |
| Zolmitriptan                          |                                                    |                           |                           |

## Authorizations

**Length of Authorizations**: 180 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Step Therapy

Step Therapy Approval Criteria

- Must have had an inadequate clinical response of at least **14 days** with at least **two preferred** drugs

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **14 days** with at least **two preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Ubrogepant (Ubrelvy)

Additional Ubrogepant (Ubrelvy) Criteria

- Must have had an inadequate clinical response of at least **14 days** with at least **one preferred** oral CGRP antagonist 
### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

**QL** - Nurtec ODT: 8 doses per 30 days for **acute** treatment

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_Criteria%20_APPROVED.pdf#page=26){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=13){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
